Recombinant erythropoietin for prevention of anemia in preterm infants

Artikel in diesem Heft

1. Titelei
2. Guest editorial
3. The oxygen sensor that controls EPO production: facts and fancies
4. Serum immunoreactive erythropoietin in health and disease
5. Announcement
6. The ontogeny of the biological role and production of erythropoietin
7. Hemopoietic-initiating cells
8. Erythropoiesis in pregnancy
9. Iron and erythropoiesis in normal subjects and in pregnancy
10. Erythropoiesis in the postpartum period
11. Erythropoietin transplacental passage — Review of animal studies
12. Lack of permeability of the human placenta for erythropoietin
13. Erythropoietin — from gene structure to therapeutic applications
14. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy
15. Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study
16. Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well?
17. rhEPO treatment of postpartum anemia
18. Recombinant erythropoietin for prevention of anemia in preterm infants
19. Erythropoietin therapy for extremely premature infants
20. Comparison of high dose therapy of rhEPO, given two or three times a week in premature infants
21. The roles and vital importance of placental blood to the newborn infant